Labiotech 15. Mai 2026 Freeze variability, not progress: strengthen your cell therapy supply chain from the start
Labiotech 7. Mai 2026 The rise of trispecific antibodies: Biopharma’s next big bet after bispecifics
Labiotech 29. Apr. 2026 When ADCs meet targeted protein degraders: The emerging field of degrader-antibody conjugates